Item 8.01. Other Events.



On August 4, 2021, Veracyte, Inc. (the "Company") filed a prospectus supplement
("Prospectus Supplement") to its effective shelf registration statement on Form
S-3ASR (File No. 333-252681) filed with the Securities and Exchange Commission
on February 3, 2021. The Company filed the Prospectus Supplement for the purpose
of registering for resale up to 3,347,493 shares of the Company's common stock
issued in connection with the Company's acquisition of HalioDx SAS, a French
société par actions simplifiée, on August 2, 2021.

In connection with the filing of the Prospectus Supplement, the Company is
filing an opinion of its counsel, Fenwick & West LLP, regarding the legality of
the common stock being registered, which opinion is attached as Exhibit 5.1 to
this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

Exhibit No.               Description

        5.1                 O    pinion of Fenwick & W    est LLP.
       23.1                 Consent of Fenwick & West LLP (contained in Exhibit 5.1).
        104               Cover Page Interactive Data File (embedded within

the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses